Compare · AZN vs KROS
AZN vs KROS
Side-by-side comparison of AstraZeneca PLC (AZN) and Keros Therapeutics Inc. (KROS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and KROS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 1136.1x KROS ($231.6M).
- Over the past year, AZN is down 9.9% and KROS is down 21.6% - AZN leads by 11.7 points.
- AZN has been more active in the news (13 items in the past 4 weeks vs 10 for KROS).
- AZN has more recent analyst coverage (25 ratings vs 22 for KROS).
- Company
- AstraZeneca PLC
- Keros Therapeutics Inc.
- Price
- $169.66+1.75%
- $11.69+8.34%
- Market cap
- $263.10B
- $231.6M
- 1M return
- -0.09%
- +14.61%
- 1Y return
- -9.89%
- -21.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 13
- 10
- Recent ratings
- 25
- 22
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Keros Therapeutics Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
Latest KROS
- Chief Legal Officer Cho Esther sold $46,151 worth of shares (4,485 units at $10.29), decreasing direct ownership by 11% to 35,770 units (SEC Form 4) to satisfy tax liability
- Director Newton Charles W. sold $5,675 worth of shares (551 units at $10.30) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 12,114 units (SEC Form 4)
- Chief Scientific Officer Lerner Lorena Raquel sold $36,715 worth of shares (3,568 units at $10.29), decreasing direct ownership by 11% to 27,559 units (SEC Form 4) (for withholding tax)
- Corp. Controller & VP, Finance Tanini Annita sold $12,595 worth of shares (1,224 units at $10.29), decreasing direct ownership by 3% to 45,144 units (SEC Form 4) (withholding tax)
- Director Bienaime Jean Jacques bought $10,270 worth of shares (1,000 units at $10.27), increasing direct ownership by 5% to 19,592 units (SEC Form 4)
- New insider Tanini Annita claimed ownership of 46,368 shares (SEC Form 3)
- Keros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Keros Therapeutics Inc.
- Keros Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Keros Therapeutics Reports Second Quarter 2026 Financial Results